CA2561159A1 - Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases - Google Patents

Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases Download PDF

Info

Publication number
CA2561159A1
CA2561159A1 CA002561159A CA2561159A CA2561159A1 CA 2561159 A1 CA2561159 A1 CA 2561159A1 CA 002561159 A CA002561159 A CA 002561159A CA 2561159 A CA2561159 A CA 2561159A CA 2561159 A1 CA2561159 A1 CA 2561159A1
Authority
CA
Canada
Prior art keywords
cells
compound
ppar
disease
invitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002561159A
Other languages
English (en)
French (fr)
Inventor
Karen Chandross
Jean Merrill
Anne Minnich
Lan Lee
Olga Khorkova
Yun Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2561159A1 publication Critical patent/CA2561159A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002561159A 2004-04-01 2005-03-29 Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases Abandoned CA2561159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55853304P 2004-04-01 2004-04-01
US60/558,533 2004-04-01
PCT/US2005/010371 WO2005097098A2 (en) 2004-04-01 2005-03-29 Use of ppr delta agonists for treating demyelinating diseases

Publications (1)

Publication Number Publication Date
CA2561159A1 true CA2561159A1 (en) 2005-10-20

Family

ID=34977094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561159A Abandoned CA2561159A1 (en) 2004-04-01 2005-03-29 Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases

Country Status (16)

Country Link
US (1) US20070149580A1 (enExample)
EP (1) EP1737440A2 (enExample)
JP (1) JP2007530703A (enExample)
KR (1) KR20060134191A (enExample)
CN (1) CN1950077A (enExample)
AU (1) AU2005231358A1 (enExample)
BR (1) BRPI0509540A (enExample)
CA (1) CA2561159A1 (enExample)
IL (1) IL178165A0 (enExample)
MA (1) MA28561B1 (enExample)
MX (1) MXPA06011218A (enExample)
NO (1) NO20064985L (enExample)
RU (1) RU2006138495A (enExample)
SG (1) SG138623A1 (enExample)
WO (1) WO2005097098A2 (enExample)
ZA (1) ZA200607850B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
CN101336113B (zh) * 2005-11-28 2015-07-29 千寿制药株式会社 包括ppar激动剂的药物
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
CA2727373A1 (en) 2008-06-09 2009-12-17 Sanofi-Aventis Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
US20130117868A1 (en) 2009-12-17 2013-05-09 Sanofi Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo Imaging
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2021092279A1 (en) * 2019-11-06 2021-05-14 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤

Also Published As

Publication number Publication date
NO20064985L (no) 2006-10-31
WO2005097098A2 (en) 2005-10-20
KR20060134191A (ko) 2006-12-27
CN1950077A (zh) 2007-04-18
IL178165A0 (en) 2008-03-20
US20070149580A1 (en) 2007-06-28
SG138623A1 (en) 2008-01-28
BRPI0509540A (pt) 2007-09-18
MXPA06011218A (es) 2007-01-16
JP2007530703A (ja) 2007-11-01
WO2005097098A3 (en) 2005-12-22
MA28561B1 (fr) 2007-04-03
AU2005231358A1 (en) 2005-10-20
ZA200607850B (en) 2008-10-29
RU2006138495A (ru) 2008-05-10
EP1737440A2 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
Granneman et al. Member of the peroxisome proliferator–activated receptor family of transcription factors is differentially expressed by oligodendrocytes
US20070149580A1 (en) Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
Whitney et al. Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons
WO2015131788A1 (en) Treatment of neurological conditions
EP1022330A2 (en) Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
Jana et al. Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β
JP2010528016A (ja) 細胞を刺激するための方法および組成物
Wu et al. IL-10 protects against OPC ferroptosis by regulating lipid reactive oxygen species levels post stroke
US7132287B2 (en) Method for neural stem cell differentiation using 5HT-1A agonists
US9028810B2 (en) Composition for inducing migration of neural stem cells containing periostin as effective ingredient
Hu et al. Fasudil may induce the differentiation of bone marrow mesenchymal stem cells into neuron‑like cells via the Wnt/β‑catenin pathway
Zhang et al. Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system
Fischer et al. Fgf15-mediated control of neurogenic and proneural gene expression regulates dorsal midbrain neurogenesis
CN113433324A (zh) Nck1蛋白作为标志物在诊断脊髓损伤中的应用
Yao et al. In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes
EP3615022B1 (en) Small organic molecules for use in the treatment of neuroinflammatory disorders
US20090155223A1 (en) Cell-based compositions and methods for treating conditions of the nervous system
EP2741759A2 (en) Oligodendrocyte differentiation
HK1102384A (en) Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
US20210186903A1 (en) Treatment for demyelinating disease
Meng et al. PPAR-γ Agonist Promotes Proliferation of Neural Stem Cells Via Mitophagy Inhibition
Bennett Perturbations in oligodendrocyte progenitor growth and differentiation: Neurofibromin and FGF2 signaling
WO2008122087A1 (en) Methods for treating pervasive developmental disorders
Van Heyningen Control of glial progenitor cell number in the developing central nervous system
Blackwood The Role Of Jagged1 In The Subventricular Zone During Late Embryonic Development

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued